Sanofi
VC Fund
Paris, France
Sanofi is a VC fund in Paris focused on Biotechnology and Health Care. Sanofi offers research, development, manufacturing, and marketing of innovative therapeutic solutions. It covers areas such as diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health, and the new G enzyme.
- Total investments:
- 68
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Sanofi invests in
Stages Sanofi invests in
Countries Sanofi invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 13 contacts → | |||
Round size
- Series A
- $3M–$400M
- Series B
- $7.5M–$80M
- Post-IPO Equity
- $7.5M–$200M
Investment Focus
Industry
- Biotechnology 36 (53%)
- Health Care 25 (37%)
- Medical 18 (26%)
- Pharmaceutical 18 (26%)
- Therapeutics 13 (19%)
Stage
- Post-IPO Equity 11 (16%)
- Series B 8 (12%)
- Series A 7 (10%)
- Corporate Round 6 (9%)
- Seed 4 (6%)
Country
- United States 28 (41%)
- France 5 (7%)
- China 3 (4%)
- Egypt 1 (1%)
- Canada 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jon Fairest
Global Head of Trade and Revenue
|
Global Head of Trade and Revenue | Total investments: 2 | Find email | |
|
William Napoli
Principal Engineer
|
Principal Engineer | Total investments: 0 | Find email | |
Christophe Hirtz
Source to Pay project Lead
|
Source to Pay project Lead | Total investments: 0 | Find email | |
Frank Nestle
Global Head of Research and Chief Scientific Officer
|
Global Head of Research and Chief Scientific Officer | Total investments: 1 | Find email | |
Franqui Jimenez
Business Partner Rare Disease Cluster, Global MSAT
|
Business Partner Rare Disease Cluster, Global MSAT | Total investments: 0 | Find email | |
| See all 13 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| InduPro is a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies. | $77M / Series B / Aug 12, 2026 | ||
| Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. Italso a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives.Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting.Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA. | $7.5M / Post-IPO Equity / Jul 24, 2026 | ||
| CILcare specializes in providing drug solutions for hearing and ear disorders. | Corporate Round / Jun 23, 2026 | ||
| Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $50M / Series B / Jun 18, 2026 | ||
| Earendil Labs is a biotechnology company developing technology platforms that transform therapeutic protein discovery. | $787M / Venture - Series Unknown / Mar 20, 2026 | ||
| Altesa is a clinical-stage biopharmaceutical company dedicated to accelerating the development of new treatments against age-old threats to human health: high-consequence viral pathogens. | $75M / Series B / Feb 19, 2026 | ||
GluBio Therapeutics
|
GluBio Pharmaceutical focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules. | $30M / Corporate Round / Feb 11, 2026 | |
| National MPS Society exists to cure, and support people affected by Mucopolysaccharidoses and Mucolipidosis through supporting research. | Grant / Feb 05, 2026 | ||
| Sensorion, a Clapiers, France-based biopharmaceutical company specifically dedicated to the development of innovative and targeted therapeutic solutions to treat vestibular deficits. | $71.5M / Post-IPO Equity / Jan 28, 2026 | ||
| Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases. | $197M / Series A / Jan 08, 2026 | ||
| See all 68 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Sanofi invest in?
Sanofi invests primarily in Biotechnology, Health Care and Medical startups, most often at Post-IPO Equity and Series B stage. Most of the 68 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sanofi's check size?
Sanofi typically joins rounds of $3M–$400M at Series A, $7.5M–$80M at Series B and $7.5M–$200M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sanofi participates in.
How do I contact Sanofi?
Public channels for Sanofi include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sanofi?
The team at Sanofi includes Jon Fairest (Global Head of Trade and Revenue), William Napoli (Principal Engineer) and Christophe Hirtz (Source to Pay project Lead), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
